Were Analysts Bearish Celgene Corporation (NASDAQ:CELG) This Week?

Celgene Corporation (NASDAQ:CELG) Logo
Investors sentiment increased to 0.76 in 2019 Q1. Its up 0.12, from 0.64 in 2018Q4. It improved, as 108 investors sold Celgene Corporation shares while 441 reduced holdings. 204 funds opened positions while 213 raised stakes. 482.72 million shares or 1.75% less from 491.33 million shares in 2018Q4 were reported.
585,327 are owned by Gabelli Funds Lc. California-based Advisor Prtn Ltd Liability Corporation has invested 0.23% in Celgene Corporation (NASDAQ:CELG). 256 are held by Howe Rusling. Com Bancorp accumulated 136,753 shares or 0.15% of the stock. Martin Invest Limited Liability Com owns 2.65% invested in Celgene Corporation (NASDAQ:CELG) for 107,759 shares. Kbc Grp Inc Nv stated it has 378,086 shares. Hikari Pwr Ltd has invested 0.35% in Celgene Corporation (NASDAQ:CELG). York Capital Mgmt Global Advsrs Limited Liability reported 271,149 shares or 1.15% of all its holdings. Charles Schwab Investment Mgmt owns 3.08M shares. Paragon Lc reported 0.03% of its portfolio in Celgene Corporation (NASDAQ:CELG). Tiedemann Advsrs Ltd Liability Corporation has invested 0.03% in Celgene Corporation (NASDAQ:CELG). 42,888 were reported by Cambridge Inv Research Advisors Inc. Community Bank Na reported 3,922 shares or 0.07% of all its holdings. Kopp Advsrs Ltd Liability invested 0.26% of its portfolio in Celgene Corporation (NASDAQ:CELG). Sequoia Advisors Ltd accumulated 54,356 shares.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 5 analysts covering Celgene (NASDAQ:CELG), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Celgene has $103 highest and $95 lowest target. $100.20’s average target is 7.38% above currents $93.31 stock price. Celgene had 16 analyst reports since February 26, 2019 according to SRatingsIntel. The firm has “Buy” rating given on Monday, June 24 by Mizuho. The firm earned “Buy” rating on Thursday, February 28 by Robert W. Baird. The rating was maintained by Cantor Fitzgerald with “Hold” on Monday, June 24. The firm has “Buy” rating given on Thursday, February 28 by Cantor Fitzgerald. The firm has “Buy” rating by Jefferies given on Thursday, February 28. The rating was maintained by Robert W. Baird with “Buy” on Tuesday, March 12. Below is a list of Celgene Corporation (NASDAQ:CELG) latest ratings and price target changes.

24/06/2019 Broker: Mizuho Rating: Buy New Target: $103 Maintain
24/06/2019 Broker: Cantor Fitzgerald Rating: Hold New Target: $100 Maintain
03/05/2019 Broker: BidaskScore Rating: Hold Upgrade
03/05/2019 Broker: Barclays Capital Old Rating: Overweight New Rating: Equal-Weight Downgrade
26/04/2019 Broker: BidaskScore Rating: Sell Downgrade
05/04/2019 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Neutral Downgrade
01/04/2019 Broker: Bernstein Old Rating: Outperform New Rating: Market Perform Downgrade
01/04/2019 Broker: UBS Old Rating: Buy New Rating: Neutral Downgrade
01/04/2019 Broker: Atlantic Securities Old Rating: Overweight New Rating: Neutral Downgrade
26/03/2019 Broker: Canaccord Genuity Rating: Hold Maintain

The stock increased 0.45% or $0.42 during the last trading session, reaching $93.31. About 2.19M shares traded. Celgene Corporation (NASDAQ:CELG) has risen 3.32% since August 15, 2018 and is uptrending. It has outperformed by 3.32% the S&P500.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. The company has market cap of $66.13 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. It has a 12.75 P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Nasdaq.com which released: “After-Hours Earnings Report for July 30, 2019 : AAPL, AMGN, GILD, MDLZ, CELG, PSA, AMD, ALL, EQR, OKE, EA, VRSK – Nasdaq” on July 30, 2019, also Nasdaq.com with their article: “Why Bristol-Myers Squibb Stock Is Stumbling Ahead of Earnings – Nasdaq” published on July 23, 2019, Seekingalpha.com published: “Celgene: Timing The Switch To Bristol-Myers – Seeking Alpha” on August 08, 2019. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Nasdaq.com and their article: “Stock Market Today: Boeing, Tesla Tumble on More Worries – Nasdaq” published on July 25, 2019 as well as Nasdaq.com‘s news article titled: “Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation – Nasdaq” with publication date: July 23, 2019.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.